NVSbenzinga

Novartis Subsidiary Launches Offer to Acquire All Outstanding Shares of Regulus Therapeutics for $7.00 in Cash Plus Additional $7.00 Contingent Value Right Per Share, with Offer Expiring at 12:01 A.M. ET on June 25, 2025, Unless Extended or Terminated

Summary

No summary available.

Original Article

Read the full article from the original source for complete details and context.

Read Full Article

Article published on May 27, 2025 by benzinga